Literature DB >> 20042718

Designing early detection programs for ovarian cancer.

Patricia Hartge.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20042718      PMCID: PMC6284252          DOI: 10.1093/jnci/djp450

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs
Journal:  Lancet Oncol       Date:  2009-03-11       Impact factor: 41.316

2.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.

Authors:  Garnet L Anderson; Martin McIntosh; Lieling Wu; Matt Barnett; Gary Goodman; Jason D Thorpe; Lindsay Bergan; Mark D Thornquist; Nathalie Scholler; Nam Kim; Kathy O'Briant; Charles Drescher; Nicole Urban
Journal:  J Natl Cancer Inst       Date:  2009-12-30       Impact factor: 13.506

3.  Results from four rounds of ovarian cancer screening in a randomized trial.

Authors:  Edward Partridge; Aimee R Kreimer; Robert T Greenlee; Craig Williams; Jian-Lun Xu; Timothy R Church; Bruce Kessel; Christine C Johnson; Joel L Weissfeld; Claudine Isaacs; Gerald L Andriole; Sheryl Ogden; Lawrence R Ragard; Saundra S Buys
Journal:  Obstet Gynecol       Date:  2009-04       Impact factor: 7.623

4.  Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design.

Authors:  Margaret S Pepe; Ziding Feng; Holly Janes; Patrick M Bossuyt; John D Potter
Journal:  J Natl Cancer Inst       Date:  2008-10-07       Impact factor: 13.506

  4 in total
  7 in total

1.  Musashi-1 Expression is a Prognostic Factor in Ovarian Adenocarcinoma and Correlates with ALDH-1 Expression.

Authors:  Pu-xiang Chen; Qiao-yan Li; Zhulin Yang
Journal:  Pathol Oncol Res       Date:  2015-05-14       Impact factor: 3.201

2.  Study of the molecular recognition of aptamers selected through ovarian cancer cell-SELEX.

Authors:  Dimitri Van Simaeys; Dalia López-Colón; Kwame Sefah; Rebecca Sutphen; Elizabeth Jimenez; Weihong Tan
Journal:  PLoS One       Date:  2010-11-01       Impact factor: 3.240

Review 3.  Aptamers from cell-based selection for bioanalytical applications.

Authors:  Weihong Tan; Michael J Donovan; Jianhui Jiang
Journal:  Chem Rev       Date:  2013-03-19       Impact factor: 60.622

4.  MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study.

Authors:  E Krasniqi; A Sacconi; G Blandino; P Vici; D Marinelli; L Pizzuti; M Mazzotta; D Sergi; E Capomolla; S Donzelli; M Carosi; A Bagnato; T Gamucci; S Tomao; C Natoli; P Marchetti; A Grassadonia; N Tinari; M De Tursi; E Vizza; G Ciliberto; L Landi; F Cappuzzo; M Barba
Journal:  Biomark Res       Date:  2021-07-13

5.  Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation.

Authors:  Furong Dai; Yi Zhang; Xin Zhu; Nianchun Shan; Yuxiang Chen
Journal:  Target Oncol       Date:  2012-11-20       Impact factor: 4.493

6.  Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.

Authors:  Marco Tomasetti; Lory Santarelli
Journal:  Cancers (Basel)       Date:  2010-04-14       Impact factor: 6.639

7.  Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer.

Authors:  Hongxiao Chen; Xiufang Tian; Yajing Luan; Hui Lu
Journal:  Technol Cancer Res Treat       Date:  2019 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.